Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04440982
Recruitment Status : Recruiting
First Posted : June 22, 2020
Last Update Posted : August 17, 2022
National Cancer Institute (NCI)
Massachusetts General Hospital
Information provided by (Responsible Party):
Lumicell, Inc.

Brief Summary:
This is a prospective, multi-center, randomized, clinical trial evaluating patients undergoing breast conserving surgery using the LUM Imaging System.

Condition or disease Intervention/treatment Phase
Breast Cancer Neoadjuvant Therapy Combination Product: Study Device Arm Phase 2

Detailed Description:

Detailed Description:

All subjects will be injected with LUM015. The injection of the study drug will occur 2-6 hours prior to surgery at a dose of 1.0 mg/kg. For all subjects, surgeons will perform main specimen resection per standard of care. For subjects randomized to the intervention arm, the surgeon will use the Lum System to scan and image all orientations within the cavity and The LUM Imaging System will guide shave removal. Then, for all subjects (control and intervention arm), comprehensive shaved margins are removed.

In this study, the initial cohort is a "training set" with 10 patients receiving neoadjuvant therapy to refine the tumor detection algorithm, if needed. After completion of enrollment of the initial 10 subjects for algorithm training, the Investigators will then enroll a cohort of patients who received neoadjuvant therapy to further evaluate the performance of the LUM Imaging System in this important subset of breast cancer patients. Concurrently to the enrollment of this cohort, surgeons will also enroll a cohort of patients who did not receive neoadjuvant therapy prior to surgery. Patients will be randomized 3:1 to a LUM-assisted lumpectomy versus a standard lumpectomy. In both arms, shaved margins will be taken from the entire lumpectomy cavity to compare the extent of residual tumor after standard and LUM-assisted lumpectomies to evaluate the negative predictive value of the LUM Imaging System following neoadjuvant therapy. Only the group of patients randomized to the device (intervention) arm will have the LUM Imaging System guide the removal of tissue prior to the removal of final comprehensive shaves of the entire cavity.

Study treatment ends when the surgery is completed. Patients are followed for adverse events until their standard of care follow-up visit or after any secondary surgery, whichever is longer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 323 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will be randomized to receive the device intervention. All subjects will receive the study drug.
Masking: Single (Investigator)
Masking Description: Masking will only be applied until main lumpectomy is removed. At time of randomization, the study arm will be revealed to the study team.
Primary Purpose: Other
Official Title: Feasibility Study to Evaluate Performance of the LUM Imaging System for Intraoperative Detection of Residual Tumor in Breast Cancer Patients Receiving and Not Receiving Neoadjuvant Therapy
Actual Study Start Date : September 1, 2020
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Device Intervention: LUM Imaging System used during surgery
The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015
Combination Product: Study Device Arm
LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
Other Name: LUM Imaging System

No Intervention: Standard of Care Arm
The LUM Imaging Device will not be used to guide additional tissue removal. Patients in this arm will receive the study drug, LUM015.

Primary Outcome Measures :
  1. Development and validation of tumor detection algorithms in breast cancer patients receiving neoadjuvant therapy [ Time Frame: 1 month ]
    Refining of the previously validated tumor detection algorithm in breast cancer patients receiving neoadjuvant therapy will be conducted in the first cohort and the validation of this algorithm will use data from the second cohort.

  2. Number of patients with reported adverse events [ Time Frame: 14 days ]
    Reported adverse events will be assessed and aggregated according to event type, relation to device or drug, and severity.

  3. Reduction in residual tumor [ Time Frame: 3 months ]
    Evaluate reduction in residual tumor left after Lumicell assisted lumpectomy compared with SoC removal of main lumpectomy specimen in patients who have received and not received neo-adjuvant therapy

  4. Report on patient reported outcomes and patient preference information [ Time Frame: 12 months ]
    Collect and summarize patient reported information on outcomes and preference

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have histologically or cytologically confirmed primary invasive breast cancer, ductal carcinoma in situ (DCIS) or primary invasive breast cancer with a DCIS component.
  • Female, age of 18 years or older.
  • Subjects must have received neoadjuvant therapy for this breast cancer diagnosis prior to their lumpectomy procedure (cohorts 1 and 2).
  • Subjects must be scheduled for a lumpectomy for a breast malignancy.
  • Subjects must be able and willing to follow study procedures and instructions.
  • Subjects must have received and signed an informed consent form.
  • Subjects must have no uncontrolled serious medical problems except for the diagnosis of cancer, as per the exclusion criteria listed below.

    • Leukocytes > 1,000/mcL
    • Platelets > 50,000/mcL
    • total bilirubin within normal institutional limits
    • AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal
    • eGFR >= 60mL/min/1.73m2
  • Subjects with ECOG performance status of 0 or 1.

Exclusion Criteria:

  • Subjects who have been diagnosed with bilateral breast cancer and are undergoing bilateral resection procedure.
  • Subjects who are pregnant at the time of diagnosis of their breast cancer. Breastfeeding should be discontinued if the mother is treated with LUM015.
  • Subjects who are sexually active and not willing/able to use medically acceptable forms of contraception (hormonal or barrier method of birth control, abstinence) upon entering the study and for 60 days after injection of LUM015.
  • Subjects who have taken an investigational drug within 14 days of enrollment.
  • Subjects who will have administration of methylene blue or any blue or green dye for sentinel lymph node mapping on the day of the surgery prior to imaging the lumpectomy cavity with the LUM Imaging Device.
  • Subjects who have not recovered from adverse events due to other pharmaceutical or diagnostic agents.
  • Subjects with uncontrolled hypertension defined as persistent systolic blood pressure > 180 mm Hg, or diastolic blood pressure > 110 mm Hg; those subjects with known HTN should be stable within these ranges while under pharmaceutical therapy.
  • Subjects with a history of allergic reaction to polyethylene glycol (PEG).
  • Subjects with a history of allergic reaction to any oral or intravenous contrast agents.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, COPD or asthma requiring hospitalization within the past 12 months, or psychiatric illness/social situations that would limit compliance with study requirements.
  • HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with LUM015.
  • Any subject for whom the investigator feels participation is not in the best interest of the subject.
  • Subjects undergoing a second lumpectomy procedure because of positive margins in a previous surgery prior to entering this study.
  • Subjects with prior ipsilateral breast cancer surgeries, mastectomies, breast reconstructions or implants.
  • Subjects who have undergone a surgical biopsy for any reason in the ipsilateral breast performed less than 2 years prior to enrollment of this study.
  • Subjects with prior ipsilateral reduction mammoplasties (breast reductions) performed less than 2 years prior to enrollment to this study.
  • Subjects undergoing breast conserving surgery whose resected specimen (main lump, shaves, or any other resected tissue) will be evaluated with frozen section after the Lumicell-guided removal of shaves.
  • Subjects with a history of allergic reaction to Tegaderm

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04440982

Layout table for location contacts
Contact: Jorge Ferrer, PhD 617-404-1040
Contact: Kate Smith, MPH, CCRP 617-404-1033

Layout table for location information
United States, California
Stanford Hospital and Clinics Recruiting
Palo Alto, California, United States, 94304
Contact: Irene Wapnir, MD         
Principal Investigator: Irene Wapnir, MD         
United States, Florida
Morton Plant Mease Health Care Oncology Research Recruiting
Clearwater, Florida, United States, 33756
Contact: Peter Blumencranz         
Principal Investigator: Peter Blumencranz, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Barbara Smith, MD, PhD         
Principal Investigator: Barbara Smith, MD, PhD         
United States, North Carolina
Duke Cancer Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Shelley Hwang, MD         
Principal Investigator: Shelley Hwang, MD         
Novant Health Cancer Center Recruiting
Winston-Salem, North Carolina, United States, 27103
Contact: David Carr         
Principal Investigator: David Carr, MD         
United States, Texas
The University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Kelly Hunt, MD         
Principal Investigator: Kelly Hunt, MD         
Sponsors and Collaborators
Lumicell, Inc.
National Cancer Institute (NCI)
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Barbara Smith, MD, PhD Massachusetts General Hospital
Study Director: Jorge Ferrer, PhD Lumicell, Inc.
Layout table for additonal information
Responsible Party: Lumicell, Inc. Identifier: NCT04440982    
Other Study ID Numbers: CLP0008
1R01CA212138-01 ( U.S. NIH Grant/Contract )
First Posted: June 22, 2020    Key Record Dates
Last Update Posted: August 17, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Lumicell, Inc.:
breast cancer surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases